Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Acne Vulgaris Therapeutics Pipeline Analysis Report 2017 - Clinical Trials & Results, Patent, Designations, and Collaborations -

Research and Markets
Posted on: 15 Mar 18

The "Acne Vulgaris Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designations, Collaborations, and Other Developments" report has been added to's offering.

Various drug candidates have shown positive clinical results and are proceeding towards further development. For instance, In May 2017, Foamix Ltd. announced that FMX101 was generally safe and well tolerated with no drug-related serious adverse events from two double-blind, randomized, placebo-controlled Phase III trials for the treatment of moderate-to-severe acne vulgaris. AndroScience Corporation announced that ASC-J9 in a cream formulation demonstrated a therapeutic effect in lowering lesion counts in moderate to severe acne.

According to the research findings, the drug candidates in acne vulgaris pipeline have move from small molecule towards biologics and peptides. Allergan plc is in the process of manufacturing ANT-1207, also known as botulinum toxin A topical, under the Phase II stage of development for the treatment of acne vulgaris. The therapeutic candidate is an anticholinergic agent, being developed to be administered by topical route. Helix Biomedix, Inc. in a process of developing peptide based molecule, which is in the unknown stage for the treatment of acne vulgaris.

Most of the companies possess advanced technologies for the development of acne vulgaris. For instance, Sol-Gel Technologies Ltd. introduced a technology known as sol-gel, in which silica on site forms a microcapsule shells and release drugs at site of action. The drug substance that is added during the sol-gel reaction is encapsulated, through which a core-shell structure is formed. Therefore, the contribution of advanced technologies for making targeted therapies is a key factor driving the growth of acne vulgaris pipeline therapeutics.

Report Segmentation

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

Key Topics Covered

Chapter 1. Research Background

Chapter 2. Research Methodology

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

Chapter 5. Acne Vulgaris Therapeutics Pipeline Analysis by Phase (2017)

Chapter 6. Clinical Trials Analysis

Chapter 7. Competitive Landscape

Chapter 8. Company Profiles

  • Promius Pharma, LLC (subsidiary of Dr. Reddy's Laboratories Ltd.)
  • Realm Therapeutics, Inc.
  • Sienna Biopharmaceuticals, Inc.
  • Sol-Gel Technologies Ltd.

For more information about this report visit

View source version on

Business Wire

Last updated on: 15/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.